Anixa Biosciences, Inc.
ANIX · NASDAQ
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $210 | $2,469,000 | $513 |
| % Growth | -100% | -100% | 481,656.1% | – |
| Cost of Goods Sold | $37 | $161 | $42 | $385 |
| Gross Profit | -$37 | $49 | $2,468,958 | $127 |
| % Margin | – | 23.3% | 100% | 24.9% |
| R&D Expenses | $6,396 | $4,769 | $6,703 | $6,190 |
| G&A Expenses | $7,435 | $6,291 | $7,172 | $7,073 |
| SG&A Expenses | $7,435 | $6,291 | $7,172 | $7,073 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13,831 | $11,060 | $13,875 | $13,263 |
| Operating Income | -$13,831 | -$11,011 | -$13,875 | -$13,136 |
| % Margin | – | -5,243.3% | -0.6% | -2,563.1% |
| Other Income/Exp. Net | $1,133 | $1,081 | $104 | -$174 |
| Pre-Tax Income | -$12,698 | -$9,930 | -$13,771 | -$13,309 |
| Tax Expense | $0 | $0 | $0 | -$181 |
| Net Income | -$12,554 | -$9,811 | -$13,491 | -$12,947 |
| % Margin | – | -4,671.9% | -0.5% | -2,526.2% |
| EPS | -0.39 | -0.32 | -0.44 | -0.45 |
| % Growth | -21.9% | 27.3% | 2.2% | – |
| EPS Diluted | -0.39 | -0.32 | -0.44 | -0.45 |
| Weighted Avg Shares Out | 31,898 | 30,980 | 30,374 | 28,579 |
| Weighted Avg Shares Out Dil | 31,898 | 30,980 | 30,374 | 28,579 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,133 | $1,081 | $104 | $2 |
| Interest Expense | $0 | $0 | $104 | $0 |
| Depreciation & Amortization | $37 | $46 | $42 | $60 |
| EBITDA | -$12,661 | -$10,965 | -$13,729 | -$13,081 |
| % Margin | – | -5,221.4% | -0.6% | -2,552.4% |